Earnings Releases·Nov 12, 2026, 7:16 AM ET

Century Therapeutics — Third Quarter 2026 Earnings Summary

Cash and investments increased to $174.1 million as of September 30, 2026, from $117.1 million in December 2025, with cash runway extending into Q1 2029.
Net loss narrowed to $23.5 million for the quarter (vs. $34.4 million prior year) and $79.6 million for the nine-month period (vs. $9.6 million net income prior year), driven by a $11.1 million lease termination charge in the nine-month period.
Operating expenses declined 30% year-over-year to $25.2 million for the quarter, with R&D down to $18.1 million due to portfolio prioritization and reduced personnel/facility costs.
Strategic progress includes FDA alignment for both CNTY-813 and CNTY-308 programs, with CNTY-308 expected to enter the clinic in 2026 and a CNTY-813 IND submission targeted for Q4 2026.
Joseph Truitt was appointed to the Board of Directors; no major M&A or capital return activities were reported.